DK3710058T3 - Anvendelse af cannabidiol ud over lamotrigin til behandling af anfald forbundet med lennox-gastauts syndrom - Google Patents
Anvendelse af cannabidiol ud over lamotrigin til behandling af anfald forbundet med lennox-gastauts syndrom Download PDFInfo
- Publication number
- DK3710058T3 DK3710058T3 DK18808075.8T DK18808075T DK3710058T3 DK 3710058 T3 DK3710058 T3 DK 3710058T3 DK 18808075 T DK18808075 T DK 18808075T DK 3710058 T3 DK3710058 T3 DK 3710058T3
- Authority
- DK
- Denmark
- Prior art keywords
- gastauts
- lennox
- cannabidiol
- lamotrigine
- syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1718862.4A GB2568471B (en) | 2017-11-15 | 2017-11-15 | Use of cannabinoids in the treatment of epilepsy |
| PCT/GB2018/053315 WO2019097238A1 (en) | 2017-11-15 | 2018-11-15 | Use of cannabinoids in the treatment of seizures associated with lennox-gastaut syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3710058T3 true DK3710058T3 (da) | 2024-11-04 |
Family
ID=60788456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18808075.8T DK3710058T3 (da) | 2017-11-15 | 2018-11-15 | Anvendelse af cannabidiol ud over lamotrigin til behandling af anfald forbundet med lennox-gastauts syndrom |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210169824A1 (enExample) |
| EP (2) | EP3710058B1 (enExample) |
| JP (2) | JP7391019B2 (enExample) |
| KR (1) | KR102786614B1 (enExample) |
| CN (1) | CN111629756A (enExample) |
| AU (2) | AU2018366443A1 (enExample) |
| BR (1) | BR112020009508A2 (enExample) |
| CA (1) | CA3082433A1 (enExample) |
| DK (1) | DK3710058T3 (enExample) |
| ES (1) | ES2991947T3 (enExample) |
| FI (1) | FI3710058T3 (enExample) |
| GB (1) | GB2568471B (enExample) |
| IL (1) | IL274633A (enExample) |
| MX (2) | MX2020005147A (enExample) |
| RU (1) | RU2020119390A (enExample) |
| WO (1) | WO2019097238A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916977D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| GB202009321D0 (en) | 2020-06-18 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| KR102891881B1 (ko) | 2020-07-16 | 2025-11-26 | 주식회사 엘지에너지솔루션 | 듀얼 슬롯 다이 코터 |
| GB2597304A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome |
| GB2597280A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with auriculotemporal syndrome |
| WO2022017936A1 (en) * | 2020-07-20 | 2022-01-27 | GW Research Limited | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB202013765D0 (en) | 2020-09-02 | 2020-10-14 | Gw Res Ltd | Method of preparing cannabinoids |
| EP4412619A4 (en) * | 2021-10-04 | 2025-11-12 | Marinus Pharmaceuticals Inc | GANAXOLONE FOR THE TREATMENT OF BOURNEVILLE'S TUBEROUS SCLEROSIS AND EPILEPTIC DISORDERS |
| EP4507689A1 (en) | 2022-04-12 | 2025-02-19 | Shackelford Pharma Inc. | Treatment of seizure disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015266897B2 (en) | 2014-05-29 | 2020-07-30 | Fresh Cut Development, Llc | Stable cannabinoid formulations |
| US20170224634A1 (en) * | 2014-05-29 | 2017-08-10 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
-
2017
- 2017-11-15 GB GB1718862.4A patent/GB2568471B/en not_active Expired - Fee Related
-
2018
- 2018-11-15 US US16/764,701 patent/US20210169824A1/en not_active Abandoned
- 2018-11-15 EP EP18808075.8A patent/EP3710058B1/en active Active
- 2018-11-15 DK DK18808075.8T patent/DK3710058T3/da active
- 2018-11-15 BR BR112020009508-7A patent/BR112020009508A2/pt unknown
- 2018-11-15 AU AU2018366443A patent/AU2018366443A1/en not_active Abandoned
- 2018-11-15 ES ES18808075T patent/ES2991947T3/es active Active
- 2018-11-15 KR KR1020207015573A patent/KR102786614B1/ko active Active
- 2018-11-15 JP JP2020526576A patent/JP7391019B2/ja active Active
- 2018-11-15 WO PCT/GB2018/053315 patent/WO2019097238A1/en not_active Ceased
- 2018-11-15 CN CN201880080175.4A patent/CN111629756A/zh active Pending
- 2018-11-15 RU RU2020119390A patent/RU2020119390A/ru unknown
- 2018-11-15 FI FIEP18808075.8T patent/FI3710058T3/fi active
- 2018-11-15 CA CA3082433A patent/CA3082433A1/en active Pending
- 2018-11-15 EP EP24200897.7A patent/EP4487860A3/en active Pending
- 2018-11-15 MX MX2020005147A patent/MX2020005147A/es unknown
-
2020
- 2020-05-13 IL IL274633A patent/IL274633A/en unknown
- 2020-07-13 MX MX2023012352A patent/MX2023012352A/es unknown
-
2023
- 2023-09-29 JP JP2023170155A patent/JP7723711B2/ja active Active
-
2024
- 2024-08-28 AU AU2024216397A patent/AU2024216397A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021502992A (ja) | 2021-02-04 |
| GB201718862D0 (en) | 2017-12-27 |
| WO2019097238A1 (en) | 2019-05-23 |
| GB2568471B (en) | 2022-04-13 |
| GB2568471A (en) | 2019-05-22 |
| EP4487860A3 (en) | 2025-04-02 |
| IL274633A (en) | 2020-06-30 |
| EP4487860A2 (en) | 2025-01-08 |
| MX2023012352A (es) | 2023-10-31 |
| CA3082433A1 (en) | 2020-05-15 |
| AU2018366443A1 (en) | 2020-06-11 |
| AU2024216397A1 (en) | 2024-09-19 |
| BR112020009508A2 (pt) | 2020-10-13 |
| JP2023168448A (ja) | 2023-11-24 |
| CN111629756A (zh) | 2020-09-04 |
| US20210169824A1 (en) | 2021-06-10 |
| RU2020119390A3 (enExample) | 2021-12-15 |
| RU2020119390A (ru) | 2021-12-15 |
| EP3710058B1 (en) | 2024-10-09 |
| JP7391019B2 (ja) | 2023-12-04 |
| ES2991947T3 (es) | 2024-12-05 |
| MX2020005147A (es) | 2020-08-20 |
| KR102786614B1 (ko) | 2025-03-26 |
| KR20200088356A (ko) | 2020-07-22 |
| JP7723711B2 (ja) | 2025-08-14 |
| EP3710058A1 (en) | 2020-09-23 |
| NZ764569A (en) | 2024-11-29 |
| FI3710058T3 (fi) | 2024-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3710058T3 (da) | Anvendelse af cannabidiol ud over lamotrigin til behandling af anfald forbundet med lennox-gastauts syndrom | |
| DK3364993T3 (da) | Fremgangsmåder til behandling af angelman syndrom | |
| DK3888641T3 (da) | Anvendelse af cannabidiol i behandling af anfald i forbindelse med doose-syndrom | |
| DK3687576T3 (da) | Anvendelse af cannabidiol i kombination med norfenfluramin eller fenfluramin i behandling af epilepsi | |
| DK3743053T3 (da) | Anvendelse af cannabinoider i behandling af epilepsi | |
| DK3372229T3 (da) | Fremgangsmåder til øgning af tonisk hæmning og behandling af angelmans syndrom | |
| DK3334422T3 (da) | Anvendelse af cannabidiolsyre i behandling af epilepsi | |
| DK3472317T3 (da) | Sammensætninger og fremgangsmåder til reduktion af okulær vaskularisation | |
| DK3160476T3 (da) | Substituerede nukleosider, nukleotider og analoger dertil til anvendelse til behandling af virusinfektioner | |
| DK4154882T3 (da) | Behandling af amyotrofisk lateralsklerose med pridopidin | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| GB201621480D0 (en) | Use of cannabinoids in the treatment of angelman syndrome | |
| DK3206716T3 (da) | Anvendelse af cannabinoider i behandling af atoniske anfald ved lennox-gastauts syndrom | |
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| DK3351047T3 (da) | Direkte tilgang-procedure til reduktion af latens | |
| EP3324961C0 (en) | TREATMENT OF ANGELMAN SYNDROME WITH GABOXADOL | |
| IL247354A0 (en) | Treatment of conditions associated with hyperinsulinaemia | |
| DK3865484T3 (da) | Pde9-hæmmer med imidazopyrazinon-rygrad til behandling af perifere sygdomme | |
| DK3307296T3 (da) | Timp2 til anvendelse til behandling af aldringsassocierede tilstande | |
| DK3099298T3 (da) | Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner | |
| LT3717646T (lt) | Angelmano sindromo gydymas priešprasme nukleorūgštimi | |
| DK3391902T5 (da) | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati | |
| DK3512506T3 (da) | Anvendelse af pridopidin til behandling af retts syndrom | |
| DK3273995T3 (da) | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion | |
| DK3374497T3 (da) | Modificerede makrofager til anvendelse i behandlingen af kræft |